AB Science Announces Promising Early Data from Phase 1 Trial of AML Treatment
Paris, France – AB Science today released initial data from its Phase 1 clinical trial evaluating the efficacy of masitinib in treating acute myeloid leukemia (AML), a notably aggressive form of blood cancer. The preliminary findings, presented [Date not specified in source, retain ambiguity], indicate a potential signal of anti-leukemic activity and manageable safety profiles in heavily pre-treated patients.
AML affects thousands globally each year, with limited treatment options for those who relapse or are ineligible for intensive chemotherapy.Masitinib, AB ScienceS lead compound, is a tyrosine kinase inhibitor already being investigated in other cancers and neuroinflammatory diseases.This Phase 1 trial represents a critical first step in assessing its potential too address a meaningful unmet medical need in AML, perhaps offering a new therapeutic avenue for patients with limited alternatives. Further trials will be necesary to confirm these early results and determine masitinib’s ultimate role in AML treatment.
The trial involved [Details not specified in source, retain ambiguity] patients with relapsed or refractory AML, meaning the cancer had returned after treatment or did not respond to initial therapies. Initial data highlighted [Details not specified in source, retain ambiguity] observed responses, alongside a safety profile consistent with prior masitinib studies. AB Science reported [Details not specified in source, retain ambiguity] no dose-limiting toxicities, suggesting the drug can be administered at potentially therapeutic levels.
this declaration follows a series of recent developments for AB Science, including a €2.8 million private placement in October 2025,and the completion of a €2.55 million private placement in August 2025. The company also recently obtained European authorization for a Phase 3 study [Details not specified in source,retain ambiguity] and successfully completed a private placement of €255,000 in July 2025. AB Science previously announced a prosperous private placement in July 2025 and reported a reduction in its operating deficit alongside an increase in net loss in October 2025. The company had postponed the publication of its half-yearly report in September 2025.
Disclaimer: The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an invitation to buy or sell a financial asset, nor investment advice. The reader is encouraged to carry out their own research before making any decision. Investments in the stock market involve risks, particularly capital loss.The past performance of an asset or market is no indication of its future performance. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
